Tait, R. C.
September 2001
Thorax;Sep2001 Supp, Vol. 56, pii30
Academic Journal
Background: Vitamin K antagonist treatment is effective for prevention and treatment of thromboembolic events but frequent laboratory control and dose adjustment are essential. Small portable devices have enabled patient self-monitoring of anticoagulation and self-adjustment of the dose. We compared this self-management of oral anticoagulant therapy with conventional management by a specialist anticoagulation clinic in a randomised cross-over study. Methods: 50 patients on long-term oral anticoagulant treatment were included in a randomised controlled crossover study Patients were self-managed or were managed by the anticoagulation clinic for a period of 3 months. After this period the alternative strategy was followed for each patient. Prothrombin time (expressed as international normalised ratio [INR]) were measured at intervals of 1-2 weeks in both periods without knowledge of type of management The primary endpoint was the number of measurements within the therapeutic range (therapeutic target value ±50.5 INR units). Findings: There was no significant difference in the overall quality of control of anticoagulation between the two study periods. Patients were for 55% and for 49% of the treatment period within a range of ±0.5 from the therapeutic target INR during self- management and anticoagulation clinic management, respectively (p=0.06). The proportion of patients who spent most time in the therapeutic target range was larger during self-management than during anticoagulation clinic-guided management. The odds ratio for a better control of anticoagulation (defined as the period of time in the therapeutic target range) during self-management compared with anticoagulation clinic-guided management was 4.6 (95% Cl 2.1-10.2). A patient satisfaction assessment showed superiority of self-management over conventional care. Interpretation: Self-management of INR in the population in this study is feasible and appears to result in control of anticoagulation that is at least equivalent to management by a specialist anticoagulation clinic. It is also better appreciated by patients. Larger studies are required to assess the effect of this novel management strategy on the incidence of thromboembolic or bleeding complications.


Related Articles

  • Use of patient flow analysis to improve patient visit efficiency by decreasing wait time in a primary care-based disease management programs for anticoagulation and chronic pain: a quality improvement study. Potisek, Nicholas M.; Malone, Robb M.; Shilliday, Betsy Bryant; Ives, Timothy J.; Chelminski, Paul R.; DeWalt, Darren A.; Pignone, Michael P. // BMC Health Services Research;2007, Vol. 7, p8 

    Background: Patients with chronic conditions require frequent care visits. Problems can arise during several parts of the patient visit that decrease efficiency, making it difficult to effectively care for high volumes of patients. The purpose of the study is to test a method to improve patient...

  • Multinational development of a questionnaire assessing patient satisfaction with anticoagulant treatment: the 'Perception of Anticoagulant Treatment Questionnaire' (PACT-Q). Prins, Martin H.; Marrel, Alexia; Carita, Paulo; Anderson, David; Bousser, Marie-Germaine; Crijns, Harry; Consoli, Silla; Arnould, Benoit // Health & Quality of Life Outcomes;2009, Vol. 7, p1 

    Background: The side effects and burden of anticoagulant treatments may contribute to poor compliance and consequently to treatment failure. A specific questionnaire is necessary to assess patients' needs and their perceptions of anticoagulant treatment. Methods: A conceptual model of...

  • Offering safe and effective anticoagulation management. Hill, Barry // Independent Nurse;7/20/2009, p40 

    The article presents an overview of methods which British medical personnel can use to provide safe and effective management of anticoagulation therapy which features the anticoagulant drug warfarin. A discussion of the impact that an increase in anticoagulation patients is having on the ability...

  • POINT / COUNTER. Weitz, Jeffrey; Liebman, Howard A. // Hem/Onc Today;3/25/2008, Vol. 9 Issue 5, p11 

    This article presents a debate on whether Factor IIa (thrombin) or Factor Xa appears to be a better target for oral anticoagulant therapies. One person contends that the whole idea with Factor Xa is that it only convert prothrombin to thrombin, whereas thrombin has all the other effects. Another...

  • Long-term warfarin treatment may induce arterial calcification in humans: case report. Schori, Thomas R.; Stungis, George E. // Clinical & Investigative Medicine;Apr2004, Vol. 27 Issue 2, p107 

    Purpose: To report a case of arterial calcification in a person who has had long-term treatment with warfarin. Although the anticoagulant has been shown to induce arterial calcification in laboratory animals, there have been no previous reports implicating warfarin as a clinical factor. Clinical...

  • FIVE-YEAR STUDY OF ANTICOAGULANTS. Simson, George // Angiology;May1962, Vol. 13 Issue 5, p226 

    Phenprocoumon, a newer anticoagulant, has been evaluated over a five-year period in a 45 patient-years' study. Comparision with Dicumarol is reported, and our experience with the administration and control of the drug is reviewed.

  • A profit-thinner. Becker, Cinda // Modern Healthcare;7/25/2005, Vol. 35 Issue 30, p32 

    Discusses issues concerning anticoagulant drug warfarin. Information on the anticoagulation management service at William Beaumont Hospital in Royal Oak, Michigan; Use of warfarin; Result of clinical trials on Ximelagatran conducted by AstraZeneca.

  • The new oral anticoagulants. Menajovsky, L. Bernardo; DeEugenio, Deborah // Patient Care;Nov2003, Vol. 37 Issue 11, p13 

    Presents study which discussed the use of anticoagulation therapy in the U.S. Risk associated with the administration of warfarin; Alternatives to warfarin therapy; Characteristics of an ideal anticoagulant; Existence of the accumulation of ximelagatran in patients who have severe renal...

  • Lupus Anticoagulant Assays: Questions Answered and to Be Answered. Teruya, Jun; West, Aaron G.; Suell, Mary Nell // Archives of Pathology & Laboratory Medicine;Jun2007, Vol. 131 Issue 6, p885 

    Context.—Lupus anticoagulants are antibodies with heterogenous specificities to phospholipids. They have been associated with clinical syndromes consisting of thrombosis and recurrent fetal loss. Objective.—To address questions about the laboratory assay aspects of lupus...


Read the Article


Sign out of this library

Other Topics